The present invention relates to a multi-aziridine compound having: a) at least 2 of the following structural units (A) whereby R.sub.1 is H; R.sub.2 and R.sub.4 are independently chosen from H, a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; R.sub.3 is chosen from a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; or R.sub.2 and R.sub.3 (in case R.sub.2 is different than H) may be part of the same cyclic group containing from 3 to 8 carbon atoms; R′ and R″ are independently H or an aliphatic hydrocarbon group containing from 1 to 12 carbon atoms; and b) a molecular weight of at least 600 Daltons, wherein the molecular weight is determined using MALDI-TOF mass spectrometry according to the description.

The present invention relates to a multi-aziridine compound having: a) at least 2 of the following structural units (A) whereby R.sub.1 is H; R.sub.2 and R.sub.4 are independently chosen from H, a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; R.sub.3 is chosen from a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; or R.sub.2 and R.sub.3 (in case R.sub.2 is different than H) may be part of the same cyclic group containing from 3 to 8 carbon atoms; R′ and R″ are independently H or an aliphatic hydrocarbon group containing from 1 to 12 carbon atoms; and b) a molecular weight of at least 600 Daltons, wherein the molecular weight is determined using MALDI-TOF mass spectrometry according to the description.

The present invention relates to a two-component coating system comprising a first component and a second component each of which is separate and distinct from each other, wherein the first component comprises a carboxylic acid functional polymer dissolved and/or dispersed in an aqueous medium, and the second component comprises a multi-aziridine compound having: a) from 2 to 6 of the following structural units (A): b) whereby m is an integer from 1 to 8; and o R′ and R″ are both H b) one or more linking chains wherein each one of these linking chains links two of the structural units A; c) one or more connecting groups whereby each one of the connecting groups connects two of the structural units A; and d) a molecular weight in the range from 840 Daltons to 5000 Daltons, wherein the molecular weight is measured using MALDI-TOF mass spectrometry.

##STR00001##

The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

The invention relates to particles comprising a particular (aziridinyl hydroxy)-functional organic component. The invention further relates to mixtures comprising said particles. The invention further relates to aqueous dispersions comprising said particles. The invention further relates to aqueous compositions comprising said particles. The invention further relates to coating compositions comprising said particles. The invention further relates to aqueous coating compositions comprising said particles. The invention further relates to particles obtained by a process comprising—amongst others—the steps of providing an aqueous dispersion comprising a particular (aziridinyl hydroxy)-functional organic component. The invention further relates to a kit-of-parts comprising in one of its parts an aqueous dispersion comprising a particular (aziridinyl hydroxy)-functional organic component. The invention further relates to cured forms of the various particles, mixtures, aqueous dispersions, aqueous compositions, coating compositions, and aqueous coating compositions. The invention further relates to articles comprising the particles and/or said mixtures, and/or said aqueous dispersions and/or aqueous compositions and/or said cured forms. The invention further relates to various uses of the particles and/or said mixtures, and/or said aqueous dispersions and/or aqueous compositions and/or said cured forms.

The present application relates to aziridine functional compounds with reduced genotoxicity and good crosslinking efficiency, for use in the preparation of, for example, coatings.

##STR00001##

The present application relates to aziridine functional compounds with reduced genotoxicity and good crosslinking efficiency, for use in the preparation of, for example, coatings.

##STR00001##

The present invention relates to a multi-aziridine crosslinker composition, characterized in that the multi-aziridine crosslinker composition is an aqueous dispersion having a pH ranging from 8 to 14 and comprises a multi-aziridine compound in dispersed form, wherein said multi-aziridine compound has: a. from 2 to 6 of the following structural units A: whereby R.sub.1 is H, R.sub.2 and R.sub.4 are independently chosen from H or an aliphatic hydrocarbon group containing from 1 to 4 carbon atoms, R a is an aliphatic hydrocarbon group containing from 1 to 4 carbon atoms, m is 1, b. one or more linking chains wherein each one of these linking chains links two of the structural units A; and c. a molecular weight in the range from 500 to 10000 Daltons wherein the molecular weight is determined using MALDI-TOF mass spectrometry according to the description.

##STR00001##

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.